액체생검 시장 : 용도별, 대상 질환별, 순환 바이오마커 유형별, 샘플 유형별, 최종사용자별, 방법 유형별, 주요 지역별 - 업계 동향과 세계 예측(- 2035년)

Liquid Biopsy Market by Application, Target Disease Indication, Type of Circulating Biomarker, Type of Sample, End-user, Type of Technique and Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,943,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 10,126,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 15,335,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 26,042,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 액체생검 시장 규모는 2035년까지 예측 기간 동안 15.53%의 연평균 복합 성장률(CAGR)로 확대되어 현재 60억 9,000만 달러에서 2035년까지 298억 달러로 성장할 것으로 예상됩니다.

암은 전 세계적으로 심혈관계 질환에 이어 사망원인 2위를 차지하고 있습니다. 암 조기 검진은 증상이 나타나기 전에도 질병을 발견하고 치료 가능한 단계에 있는 질병을 치료하는 데 도움이 됩니다. 또한 환자의 생존율을 향상시킬 수 있습니다. 암의 부담이 증가함에 따라 비침습적 진단에 대한 수요가 최근 몇 년동안 급증하고 있습니다.

최근 액체생검은 암 발견을 위한 효과적인 기술로 부상하고 있습니다. 지난 10년간 액체생검 플랫폼에 대한 상당한 기술 혁신이 이루어졌고, 그 결과, 저침습적 혈액 기반 액체생검 검사에 대한 규제 당국의 승인이 증가했습니다. 이러한 검사는 혈액 샘플, 혈장, 소변과 같은 체액을 사용하여 세포 유리 DNA, 순환 종양 DNA, 세포외 소포와 같은 다양한 순환 바이오마커를 확인합니다. 액체생검 시장은 유리한 투자, 지속적인 연구개발 노력, 유력 기업들의 진입 증가 등으로 개척되어 향후 큰 성장이 예상됩니다.

180개 이상의 액체생검 제품이 다양한 이해관계자들에 의해 시판/개발되고 있으며, 그 중 약 45%는 다양한 암 적응증을 검출하기 위해 차세대 시퀀싱 기술을 사용하고 있습니다.

160개에 가까운 액체생검 제품은 분석 키트와 연구소에서 개발한 검사로 구성되어 있으며, 이 중 약 55%는 순환 종양 DNA 바이오마커를 검출하는 기능을 가지고 있습니다.

지난 5년 동안 액체생검 제품 제조업체들은 약 110개의 파트너십을 맺었으며, 그 중 약 20%는 액체생검 제품/기술 개발을 위해 설립되었습니다. 이 분야의 비즈니스 기회를 발견한 여러 투자자들은 지난 9년간 약 73억 달러를 투자했습니다.

암에 대한 부담 증가와 투자 증가에 힘입어 액체생검 및 기타 비침습적 암 진단 시장은 당분간 큰 성장을 이룰 것으로 예상됩니다.

세계의 액체생검(Liquid Biopsy) 시장에 대해 조사했으며, 시장 개요와 함께 의약품 용도별/대상 질환별/순환 바이오마커 유형별/샘플 유형별/최종사용자별/방법 유형별/주요 지역별 동향, 시장 진출 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 서문

제2장 조사 방법

제3장 경제 및 기타 프로젝트 특유의 고려사항

제4장 주요 요약

제5장 서론

제6장 비침습적 암 스크리닝 및 진단

제7장 액체생검 : 시장 구도

• 본 장의 개요
• 액체생검 제품 : 시장 구도
• 액체생검 제품 제조업체
• 액체생검 제품 : 기타 액체생검 제품, 키트, 소모품
• 액체생검 제품 : 계약 서비스 제공업체

제8장 기업 개요

제9장 파트너십 및 협업

제10장 자금조달과 투자 분석

제11장 제품 경쟁력 분석

제12장 대형 제약회사의 이니셔티브

제13장 주요 인수 타겟

제14장 기타 비침습적 암 진단

제15장 시장에 대한 영향 분석 : 성장 촉진요인 및 억제요인, 기회, 과제

제16장 세계의 액체생검 시장

제17장 액체생검 시장, 용도별

제18장 액체생검 시장, 대상 질환별

제19장 액체생검 시장, 순환 바이오마커 유형별

제20장 액체생검 시장, 샘플 유형별

제21장 액체생검 시장, 방법 유형별

제22장 액체생검 시장, 최종사용자별

제23장 액체생검 시장, 주요 지역별

제24장 조사 인사이트

제25장 결론

제26장 주요 인사이트

제27장 부록 1 : 표 형식 데이터

제28장 부록 2 : 기업 및 단체 리스트

LSH

영문 목차

영문목차

LIQUID BIOPSY MARKET: OVERVIEW

As per Roots Analysis, the global liquid biopsy market is estimated to grow from USD 6.09 billion in the current year to USD 29.8 billion by 2035, at a CAGR of 15.53% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Application

• Early Cancer Diagnosis
• Patient Monitoring
• Recurrence Monitoring

Target Disease Indication

• Breast Cancer
• Gastric Cancer
• Ovarian Cancer
• Leukemia
• Head and Neck Cancer
• Cervical Cancer
• Lung Cancer
• Brain Cancer
• Colorectal Cancer
• Bladder Cancer
• Liver Cancer
• Melanoma
• Nasopharyngeal cancer
• Oesophagus Cancer
• Pancreatic Cancer
• Prostate cancer
• Sarcoma
• Thyroid Cancer

Type of Circulating Biomarker

• Cell Free DNA
• Cell Free RNA
• Circulating Tumor DNA
• Exosomes
• Others Circulating Biomarkers

Type of Sample

• Blood
• Other Samples

End-user

• Hospitals
• Research Institutes
• Other end-users

Type of Technique

• Polymerase Chain Reaction
• Next Generation Sequencing

Key Geographical Regions

• North America
• Europe
• Asia-Pacific

LIQUID BIOPSY MARKET: GROWTH AND TRENDS

Cancer remains the second leading cause of the death, after cardiovascular diseases, occurring worldwide. Early screening of cancer helps in finding and curing the disease even before the symptoms are observed, and the disease is in a curable stage. Further, it allows to improve the survival rate in patients. Owing to the growing burden of cancer, the demand for non-invasive diagnostics has observed a surge in the past few years.

In the recent past, liquid biopsy has emerged as a viable technique for cancer detection. The past decade has witnessed substantial innovation in liquid biopsy platforms that have resulted in increased regulatory approvals for minimally invasive blood based liquid biopsy tests. These tests use blood samples or other bodily fluids, such as plasma or urine to identify various circulating biomarkers, including cell free DNA, circulating tumor DNA and extracellular vesicles. Driven by lucrative investments, ongoing research and development efforts, and increased involvement of prominent players, the liquid biopsy market is anticipated to witness significant growth in the foreseen future.

LIQUID BIOPSY MARKET: KEY INSIGHTS

The report delves into the current state of the liquid biopsy market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. Over 180 liquid biopsy products are commercially available / being developed by various stakeholders; of these, ~45% use next generation sequencing techniques for the detection of various cancer indications.

2. Close to 160 liquid biopsy products comprise of assay kits and laboratory developed tests; of these, ~55% have the capability to detect circulating tumor DNA biomarkers.

3. Over the past five years, ~110 partnerships have been established by liquid biopsy product manufacturers; of these, ~20% were established for the development of liquid biopsy product / technology.

4. Having realized the opportunity in this domain, several investors have invested around USD 7.3 billion (across over 125 funding instances) in the past nine years.

5. Driven by the growing burden of cancer and increasing investments, the market for liquid biopsy and other non-invasive cancer diagnostics is poised to witness significant growth in the foreseeable future.

6. The liquid biopsy market is projected to grow at a CAGR of ~15%, till 2035; the forecasted opportunity is likely to be distributed across various disease indications and biomarkers.

7. The growing demand for different non-invasive techniques is anticipated to drive the growth of the liquid biopsy market; the market growth is likely to be the fastest in North America and Asia-Pacific.

LIQUID BIOPSY MARKET: KEY SEGMENTS

Early Cancer Diagnosis Segment is Likely to Dominate the Liquid Biopsy Market During the Forecast Period

Based on the application, the market is segmented into early cancer diagnosis, patient monitoring and recurrence monitoring. At present, early cancer diagnosis holds the maximum share of the liquid biopsy market. This trend is likely to remain the same in the coming decade.

Breast Cancer Occupies the Largest Share of the Liquid Biopsy Market

Based on the target disease indication, the market is segmented into breast cancer, gastric cancer, ovarian cancer, leukemia, head and neck cancer, cervical cancer, lung cancer, brain cancer, colorectal cancer, bladder cancer, liver cancer, melanoma, nasopharyngeal cancer, oesophagus cancer, pancreatic cancer, prostate cancer, sarcoma and thyroid cancer. Currently, breast cancer captures the highest proportion of the liquid biopsy market. It is worth highlighting that the liquid biopsy market for leukemia is likely to grow at a relatively higher CAGR.

Circulating tumor DNA is the Preferred Biomarkers of the Liquid Biopsy Market

Based on the type of circulating biomarker, the market is segmented into cell free DNA, cell free RNA, circulating tumor DNA, exosomes and others circulating biomarkers. At present, circulating tumor DNA holds the maximum share of the liquid biopsy market. It is worth highlighting that the liquid biopsy market for exosomes is likely to grow at a relatively higher CAGR.

Blood Segment is Likely to Dominate the Liquid Biopsy Market During the Forecast Period

Based on the type of sample, the market is segmented into blood and other samples. At present, blood samples hold the maximum share of the liquid biopsy market. This trend is likely to remain the same in the coming decade.

Currently, Hospitals / Laboratories Occupies the Largest Share of the Liquid Biopsy Market

Based on the end-users, the market is segmented into hospitals / laboratories, research institutes and other end-users. It is worth highlighting that, currently, hospitals / laboratories hold a larger share of the liquid biopsy market. This trend is unlikely to change in the near future.

Next-Generation Sequencing Segment is the Fastest Growing Segment of the Liquid Biopsy Market During the Forecast Period

Based on the type of technique, the market is segmented into polymerase chain reaction and next generation sequencing. At present, polymerase chain reaction holds the maximum share of the liquid biopsy market. It is worth highlighting that the liquid biopsy market for next generation sequencing is likely to grow at a relatively higher CAGR.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe and Asia-Pacific. The majority share is expected to be captured by players based in North America. It is worth highlighting that the majority share is expected to be captured by players based in North America.

Example Players in the Liquid Biopsy Market

• Amoy Diagnostics
• ArcherDX
• Biocartis
• Cell Search
• CellMax Life
• Datar Cancer Genetics
• DiaCarta, EONE-DIAGNOMICS
• Exosome Diagnostics
• GeneCast Biotechnology
• Integrated DNA Technologies
• Lucence
• MDNA Life Sciences
• Miltenyi Biotec
• NeoGenomics
• ONCODE Scientific
• OncoDNA
• QIAGEN
• PANAGENE
• Personal Genome Diagnostics
• Predicin
• ScreenCell
• Tecan
• Thermo Fisher Scientific

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Director, Mid-sized Company, US
• Innovation Director, Mid-sized Company, Spain
• Founder and Medical Director, Small Company, Australia
• Founder and Chief Executive Officer, Small Company, India
• Chief Executive Officer, Small Company, Australia
• Chairman, Small Company, US
• Founder, President and Chief Technology Officer, Small Company, US
• Former Founder, Small Company, US
• Former Chief Executive Officer and Co-founder, Small Company, US
• Former Chief Executive Officer, Mid-sized Company, US
• Chief Operating Officer and Co-Founder, Small Company, Canada
• Chief Medical Officer, Mid-sized Company, US
• Chief Scientific Officer, Small Company, Sweden
• Chief Scientific Officer, Mid-sized Company, US
• Former Marketing Director, Mid-sized Company, Belgium
• Former Sales and Marketing Manager, Small Company, Italy
• Former Strategic Technology Advisor, Small Company, Australia

LIQUID BIOPSY MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the liquid biopsy market, focusing on key market segments, including [A] application, [B] target disease indication, [C] type of circulating biomarker, [D] type of sample, [E] end-user, [F] stage of development, [G] type of product, [H] type of technique, [I] application area and [J] key geographical regions.
• Market Landscape: A comprehensive evaluation of liquid biopsy products, considering various parameters, such as [A] stage of development, [B] type of product, [C] type of sample, [D] type of technique, [E] type of circulating biomarker, [F] target disease indication, [G] application and [H] application area. In addition, it provides a list of players engaged in manufacturing liquid biopsy products, along with the information on their [I] year of establishment, [J] company size (based on number of employees), [K] location of headquarters (region), [L] location of headquarters (country), [M] most active players (in terms of number of liquid biopsy products).
• Non-Invasive Cancer Screening and Diagnosis: An overview on the need for non invasive cancer diagnostics and their importance; it also features different imaging techniques, screening assays and advanced approaches used for diagnosis of cancer along with their advantages and disadvantages.
• Company Profiles: In-depth profiles of key industry players manufacturing liquid biopsy products, focusing on [A] company overviews, [B] financial information (if available), [C] product portfolio, [D] recent developments and [E] an informed future outlook.
• Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2020, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of partner, [D] type of circulating biomarker, [E] target disease indication, [F] most active players. This section also highlights the regional distribution of partnership activity in this market.
• Funding and Investment Analysis: A detailed evaluation of the investments made in the liquid biopsy domain, encompassing seed financing, venture capital, capital raised from IPOs, secondary offerings, grants / awards, other equity and debt financing, based on several parameters, such as [A] year of investment, [B] amount invested, [C] type of funding, [D] type of circulating biomarker, [E] target disease indication, [F] application area, [G] geography, [H] most active players (in terms of number of funding instances and amount invested) and [I] leading investors (in terms of number of funding instances).
• Product Competitiveness Analysis: A comprehensive competitive analysis of liquid biopsy products, examining factors, such as [A] supplier strength, [B] product competitiveness and [C] company size.
• Big Pharma Analysis: A comprehensive examination of various initiatives focused on liquid biopsy products undertaken by major pharmaceutical companies. This analysis covers various relevant parameters, such as [A] number of initiatives, [B] type of initiative, [C] stage of development, [D] type of product, [E] type of circulating biomarker, [F] target disease indication, [G] application and [H] application area.
• Key Acquisition Targets: A detailed analysis of the key acquisition targets, taking into consideration the historical trend of the acquisition activity of the players that have acquired other firms. It offers a means for other industry stakeholders to identify potential acquisition targets.
• Other Non-Invasive Cancer Diagnostics: A detailed overview of the various non invasive diagnostic tests other than liquid biopsies, being manufactured by various companies for cancer screening and early detection.
• Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Market Segmentations
• 2.7. Key Considerations
  • 2.7.1. Demographics
  • 2.7.2. Economic Factors
  • 2.7.3. Government Regulations
  • 2.7.4. Supply Chain
  • 2.7.5. COVID Impact / Related Factors
  • 2.7.6. Market Access
  • 2.7.7. Healthcare Policies
  • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Forecasted Estimates
  • 3.2.2. Currency Coverage
    • 3.2.2.1. Overview of Major Currencies Affecting the Market
    • 3.2.2.2. Impact of Currency Fluctuations on the Industry
  • 3.2.3. Foreign Exchange Impact
    • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
    • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 3.2.4. Recession
    • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 3.2.5. Inflation
    • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

• 5.1. Chapter Overview
• 5.2. Cancer Statistics and Burden of the Disease
• 5.3. Importance of Early Cancer Detection
• 5.4. Cancer Screening and Diagnosis
• 5.5. Conventional Invasive Cancer Diagnostic Tests
  • 5.5.1. Biopsy
  • 5.5.2. Fine Needle Aspiration Biopsy
  • 5.5.3. Core Needle Aspiration Biopsy
  • 5.5.4. Vacuum-Assisted Biopsy
  • 5.5.5. Image Guided Biopsy
  • 5.5.6. Sentinel Node Biopsy
  • 5.5.7. Surgical Biopsy
  • 5.5.8. Endoscopic Biopsy
  • 5.5.9. Bone Marrow Biopsy
  • 5.5.10. Endoscopy
• 5.6. Need for Non-Invasive Approaches
• 5.7. Liquid Biopsy: Diagnosing Circulating Biomarkers
  • 5.7.1. Circulating Tumor Cells
  • 5.7.2. Circulating Tumor DNA/ Cell Free DNA
  • 5.7.3. Exosomes
• 5.8. Costs and Benefits Associated with Liquid Biopsy and Non-Invasive Tests
• 5.9. Latest Intellectual Property Trends in Non-Invasive Cancer Diagnostics
• 5.10. Challenges Associated with Non-Invasive Cancer Diagnostics
• 5.11. Future Perspectives

6. NON-INVASIVE CANCER SCREENING AND DIAGNOSIS

• 6.1. Chapter Overview
• 6.2. Diagnostic Imaging
  • 6.2.1. Magnetic Resonance Imaging (MRI)
  • 6.2.2. Mammography
  • 6.2.3. Bone Scan
  • 6.2.4. Computerized Tomography (CT) Scan
  • 6.2.5. Integrated Positron Emission Tomography (PET)- CT Scan
  • 6.2.6. Ultrasound
  • 6.2.7. X-ray Radiography (Barium Enema)
• 6.3. Screening Assays
  • 6.3.1. Circulating Tumor Marker Test
  • 6.3.2. Digital Rectal Exam (DRE)
  • 6.3.3. Fecal Occult Blood Test (FOBT)
  • 6.3.4. Multigated Acquisition (MUGA) Scan
  • 6.3.5. Papanicolaou Test and Human Papilloma Virus Test
• 6.4. Advanced Non-Invasive Approaches
  • 6.4.1. Cytogenetic / Gene Expression Studies
  • 6.4.2. Molecular Signature-based Non-Invasive Methods
  • 6.4.3. Saliva-based Oral Cancer Diagnostics
  • 6.4.4. Vital Staining
  • 6.4.5. Optical Biopsy
  • 6.4.6. Other Diagnostic Techniques

7. LIQUID BIOPSY: MARKET LANDSCAPE

• 7.1. Chapter Overview
• 7.2. Liquid Biopsy Products: Overall Market Landscape
  • 7.2.1. Analysis by Stage of Development
  • 7.2.2. Analysis by Type of Product
  • 7.2.3. Analysis by Type of Sample
  • 7.2.4. Analysis by Type of Technique
  • 7.2.5. Analysis by Type of Circulating Biomarker
  • 7.2.6. Analysis by Target Disease Indication
  • 7.2.7. Analysis by Type of Tumor
  • 7.2.8. Analysis by Application
  • 7.2.9. Analysis by Application Area
• 7.3. Liquid Biopsy Product Manufacturers
  • 7.3.1. Analysis by Year of Establishment
  • 7.3.2. Analysis by Company Size
  • 7.3.3. Analysis by Location of Headquarters (Region)
  • 7.3.4. Analysis by Location of Headquarters (Country)
  • 7.3.5. Most Active Players: Analysis by Number of Liquid Biopsy Products
• 7.4. Liquid Biopsy Products: Other Liquid Biopsy Products, Kits and Consumables
• 7.5. Liquid Biopsy Products: Contract Service Providers

8. COMPANY PROFILES

• 8.1. Chapter Overview
  • 8.1.1. Amoy Diagnostics
    • 8.1.1.1. Company Overview
    • 8.1.1.2. Liquid Biopsy Product Portfolio
    • 8.1.1.3. Recent Developments and Future Outlook
  • 8.1.2. ArcherDX
    • 8.1.2.1. Company Overview
    • 8.1.2.2. Liquid Biopsy Product Portfolio
    • 8.1.2.3. Recent Developments and Future Outlook
  • 8.1.3. DiaCarta
    • 8.1.3.1. Company Overview
    • 8.1.3.2. Liquid Biopsy Product Portfolio
    • 8.1.3.3. Recent Developments and Future Outlook
  • 8.1.4. Integrated DNA Technologies
    • 8.1.4.1. Company Overview
    • 8.1.4.2. Liquid Biopsy Product Portfolio
    • 8.1.4.3. Recent Developments and Future Outlook
  • 8.1.5. MDNA Life Sciences
    • 8.1.5.1. Company Overview
    • 8.1.5.2. Financial Information
    • 8.1.5.3. Liquid Biopsy Product Portfolio
    • 8.1.5.4. Recent Developments and Future Outlook
  • 8.1.6. NeoGenomics
    • 8.1.6.1. Company Overview
    • 8.1.6.2. Liquid Biopsy Product Portfolio
    • 8.1.6.3. Recent Developments and Future Outlook
  • 8.1.7. ONCODE Scientific
    • 8.1.7.1. Company Overview
    • 8.1.7.2. Liquid Biopsy Product Portfolio
    • 8.1.7.3. Recent Developments and Future Outlook
  • 8.1.8. QIAGEN
    • 8.1.8.1. Company Overview
    • 8.1.8.2. Financial Information
    • 8.1.8.3. Liquid Biopsy Product Portfolio
    • 8.1.8.4. Recent Developments and Future Outlook
  • 8.1.9. ScreenCell
    • 8.1.9.1. Company Overview
    • 8.1.9.2. Financial Information
    • 8.1.9.3. Liquid Biopsy Product Portfolio
    • 8.1.9.4. Recent Developments and Future Outlook
  • 8.1.10. Thermo Fisher Scientific
    • 8.1.10.1. Company Overview
    • 8.1.10.2. Financial Information
    • 8.1.10.3. Liquid Biopsy Product Portfolio
    • 8.1.10.4. Recent Developments and Future Outlook
• 8.2. Other Leading Players in Liquid Biopsy Market
  • 8.2.1. Biocartis
    • 8.2.1.1. Company Overview
    • 8.2.1.2. Liquid Biopsy Product Portfolio
  • 8.2.2. Cell Search
    • 8.2.2.1. Company Overview
    • 8.2.2.2. Liquid Biopsy Product Portfolio
  • 8.2.3. CellMax Life
    • 8.2.3.1. Company Overview
    • 8.2.3.2. Liquid Biopsy Product Portfolio
  • 8.2.4. Datar Cancer Genetics
    • 8.2.4.1. Company Overview
    • 8.2.4.2. Liquid Biopsy Product Portfolio
  • 8.2.5. EONE-DIAGNOMICS Genome Center
    • 8.2.5.1. Company Overview
    • 8.2.5.2. Liquid Biopsy Product Portfolio
  • 8.2.6. Exosome Diagnostics
    • 8.2.6.1. Company Overview
    • 8.2.6.2. Liquid Biopsy Product Portfolio
  • 8.2.7. GeneCast Biotechnology
    • 8.2.7.1. Company Overview
    • 8.2.7.2. Liquid Biopsy Product Portfolio
  • 8.2.8. Inivata
    • 8.2.8.1. Company Overview
    • 8.2.8.2. Liquid Biopsy Product Portfolio
  • 8.2.9. Lucence
    • 8.2.9.1. Company Overview
    • 8.2.9.2. Liquid Biopsy Product Portfolio
  • 8.2.10. Miltenyi Biotec
    • 8.2.10.1. Company Overview
    • 8.2.10.2. Liquid Biopsy Product Portfolio
  • 8.2.11. OncoDNA
    • 8.2.11.1. Company Overview
    • 8.2.11.2. Liquid Biopsy Product Portfolio
  • 8.2.12. PANAGENE
    • 8.2.12.1. Company Overview
    • 8.2.12.2. Liquid Biopsy Product Portfolio
  • 8.2.13. Personal Genome Diagnostics
    • 8.2.13.1. Company Overview
    • 8.2.13.2. Liquid Biopsy Product Portfolio
  • 8.2.14. Predicine
    • 8.2.14.1. Company Overview
    • 8.2.14.2. Liquid Biopsy Product Portfolio
  • 8.2.15. Tecan
    • 8.2.15.1. Company Overview
    • 8.2.15.2. Liquid Biopsy Product Portfolio

9. PARTNERSHIPS AND COLLABORATIONS

• 9.1. Chapter Overview
• 9.2. Partnership Models
• 9.3. Liquid Biopsy: Partnerships and Collaborations
  • 9.3.1. Analysis by Year of Partnership
  • 9.3.2. Analysis by Type of Partnership
  • 9.3.3. Analysis by Year and Type of Partnership
  • 9.3.4. Analysis by Purpose of Agreement
  • 9.3.5. Analysis by Type of Partner
  • 9.3.6. Analysis by Year of Partnership and Type of Partner
  • 9.3.7. Analysis by Type of Circulating Biomarker
  • 9.3.8. Analysis by Target Disease Indication
  • 9.3.9. Most Active Players: Analysis by Number of Partnerships
  • 9.3.10. Analysis by Geography
    • 9.3.10.1. Local and International Agreements
    • 9.3.10.2. Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS

• 10.1. Chapter Overview
• 10.2. Types of Funding
• 10.3. Liquid Biopsy: Funding and Investment Analysis
  • 10.3.1. Analysis by Year of Investment
  • 10.3.2. Analysis by Amount Invested
  • 10.3.3. Analysis by Type of Funding
  • 10.3.4. Analysis of Amount Invested by Type of Funding
  • 10.3.5. Analysis by Year of Investment and Type of Funding
  • 10.3.6. Analysis by Type of Circulating Biomarker
  • 10.3.7. Analysis by Target Disease Indication
  • 10.3.8. Analysis by Application
  • 10.3.9. Analysis by Geography
  • 10.3.10. Most Active Players: Analysis by Number of Funding Instances
  • 10.3.11. Most Active Players: Analysis by Amount Raised
  • 10.3.12. Most Active Investors: Analysis by Number of Funding Instances

11. PRODUCT COMPETITIVENESS ANALYSIS

• 11.1. Chapter Overview
• 11.2. Methodology
• 11.3. Assumptions and Key Parameters
• 11.4. Liquid Biopsy: Product Competitiveness Analysis
  • 11.4.1. Liquid Biopsy Assay Kits
    • 11.4.1.1. Liquid Biopsy Assay Kits Offered by Players based in North America
    • 11.4.1.2. Liquid Biopsy Assay Kits Offered by Players based in Europe
    • 11.4.1.3. Liquid Biopsy Assay Kits Offered by Players based in Asia-Pacific and Rest of the World
    • 11.4.1.4. Products Offered by Players based in Rest of the World
  • 11.4.2. Liquid Biopsy Devices
  • 11.4.3. Liquid Biopsy Software

12. BIG PHARMA INITIATIVES

• 12.1. Chapter Overview
• 12.2. Scope and Methodology
• 12.3. Liquid Biopsy Related Initiatives of Top Big Pharma Companies
  • 12.3.1. Analysis by Type of Initiative
  • 12.3.2. Analysis by Stage of Development
  • 12.3.3. Analysis by Type of Product
  • 12.3.4. Analysis by Type of Circulating Biomarker
  • 12.3.5. Analysis by Target Disease Indication
  • 12.3.6. Analysis by Application
  • 12.3.7. Analysis by Application Area

13. KEY ACQUISITION TARGETS

• 13.1. Chapter Overview
• 13.2. Scope and Methodology
• 13.3. Scoring Criteria and Key Assumptions
• 13.4. Potential Acquisition Targets in North America
• 13.5. Potential Acquisition Targets in Europe
• 13.6. Potential Acquisition Targets in Asia-Pacific and Rest of the World
• 13.7. Concluding Remarks

14. OTHER NON-INVASIVE CANCER DIAGNOSTICS

• 14.1. Chapter Overview
• 14.2. Non-Blood-based Biomarker Detection Tests
• 14.3. Fecal Occult Blood Test (FOBT) and Fecal Immunochemical Tests (FIT)
• 14.4. Pigmented Lesion Assays
• 14.5. Stool DNA (sDNA)-based Tests
• 14.6. Volatile Organic Compound (VOC) Detection Tests
• 14.7. List of Other Non-Invasive Cancer Diagnostics

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 15.1. Chapter Overview
• 15.2. Market Drivers
• 15.3. Market Restraints
• 15.4. Market Opportunities
• 15.5. Market Challenges
• 15.6. Conclusion

16. GLOBAL LIQUID BIOPSY MARKET

• 16.1. Chapter Overview
• 16.2. Key Assumptions and Methodology
• 16.3. Global Liquid Biopsy Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 16.3.1. Scenario Analysis
    • 16.3.1.1. Conservative Scenario
    • 16.3.1.2. Optimistic Scenario
• 16.4. Key Market Segmentations

17. LIQUID BIOPSY MARKET, BY APPLICATION

• 17.1. Chapter Overview
• 17.2. Key Assumptions and Methodology
• 17.3. Liquid Biopsy Market: Distribution by Application, 2018, 2023 and 2035
  • 17.3.1. Early Cancer Diagnosis: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 17.3.2. Patient Monitoring: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 17.3.3. Recurrence Monitoring: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 17.3. Data Triangulation and Validation

18. LIQUID BIOPSY MARKET, BY TARGET DISEASE INDICATION

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. Liquid Biopsy Market: Distribution by Target Disease Indication, 2018, 2023 and 2035
  • 18.3.1. Breast Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.2. Gastric Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.3. Ovarian Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.4. Leukemia: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.5. Head and Neck Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.6. Cervical Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.7. Lung Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.8. Brain Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.9. Colorectal Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.10. Bladder Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.11. Liver Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.12. Melanoma Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.13. Nasopharyngeal Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.14. Esophagus Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.15. Pancreatic Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.16. Prostate Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.17. Sarcoma: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.18. Thyroid Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 18.4. Data Triangulation and Validation

19. LIQUID BIOPSY MARKET, BY TYPE OF CIRCULATING BIOMARKER

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Liquid Biopsy Market: Distribution by Type of Circulating Biomarker, 2018, 2023 and 2035
  • 19.3.1. Circulating Tumor DNA: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 19.3.2. Cell-Free DNA: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 19.3.3. Cell-Free RNA: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 19.3.4. Exosomes: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 19.3.5. Other Circulating Biomarkers: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 19.4. Data Triangulation and Validation

20. LIQUID BIOPSY MARKET, BY TYPE OF SAMPLE

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Liquid Biopsy Market: Distribution by Type of Sample, 2018, 2023 and 2035
  • 20.3.1. Blood / Plasma Samples: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 20.3.2. Other Samples: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 20.4. Data Triangulation and Validation

21. LIQUID BIOPSY MARKET, BY TYPE OF TECHNIQUE

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. Liquid Biopsy Market: Distribution by Type of Technique, 2018, 2023 and 2035
  • 21.3.1. Polymerase Chain Reaction: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 21.3.2. Next Generation Sequencing: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 21.4. Data Triangulation and Validation

22. LIQUID BIOPSY MARKET, BY TYPE OF END-USER

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Methodology
• 22.3. Liquid Biopsy Market: Distribution by Type of End-User, 2018, 2023 and 2035
  • 22.3.1. Hospitals / Laboratories: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 22.3.2. Research Institutes: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 22.3.3. Other End-users: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 22.4. Data Triangulation and Validation

23. LIQUID BIOPSY MARKET, BY KEY GEOGRAPHICAL REGIONS

• 23.1. Chapter Overview
• 23.2. Key Assumptions and Methodology
• 23.3. Liquid Biopsy Market: Distribution by Country, 2018, 2023 and 2035
  • 23.3.1. US: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 23.3.2. UK: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 23.3.3. Germany: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 23.3.4. France: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 23.3.5. Italy: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 23.3.6. Spain: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 23.3.7. Australia: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 23.3.8. Japan: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 23.3.9. China: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 23.3.10. India: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 23.4. Data Triangulation and Validation

24. SURVEY INSIGHTS

• 24.1. Chapter Overview
• 24.2. Company Specifics of Respondents
• 24.3. Analysis by Seniority Level of Respondents
• 24.4. Analysis by Product Portfolio
• 24.5. Analysis by Type of Products / Services Offered
• 24.6. Analysis by Stage of Development of Product
• 24.7. Analysis by Application
• 24.8. Analysis by Likely Market Size

25. CONCLUSION

26. EXECUTIVE INSIGHTS

• 26.1. Chapter Overview
• 26.2. Director, Company A
• 26.3. Innovation Director, Company B
• 26.4. Founder and Chief Executive Officer, Company C
• 26.5. President and Chief Technology Officer, Company D
• 26.6. Strategic Technology Advisor, Company E
• 26.7. Founder and Medical Director, Company F
• 26.8. Chief Executive Officer, Company G
• 26.9. Chief Operating Officer, Company H
• 26.10. Chief Medical Officer, Company I
• 26.11. President and Chief Executive Officer, Company J
• 26.12. Sales and Marketing Manager, Company K
• 26.13. Marketing Director, Company L
• 26.14. Founder, Company M
• 26.15. Chief Executive Officer, Company N
• 26.16. Christer Ericsson, Chief Scientific Officer, Company O
• 26.17. Chief Executive Officer and Co-founder, Company P
• 26.18. Chief Scientific Officer, Company Q

27. APPENDIX 1: TABULATED DATA

28. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

관련자료